Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Intensity of Solicited Local Adverse Events Per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events Per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events Assessed by the Investigator;Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination;Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination;Number of Participants With One or More Adverse Events of Special Interest (AESIs);Number of Participants With One or More Serious Adverse Events (SAEs);Number of Participants With One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants With Solicited Local Adverse Events;Number of Participants With Solicited Systemic Adverse Events;Number of Participants With Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Number of Participants With Unsolicited Adverse Events;Number of Participants With Unsolicited Adverse Events Considered Related to Trial Vaccine

Duration of Solicited Local Adverse Events;Duration of Solicited Systemic Adverse Events;Intensity of Solicited Local Adverse Events Per the FDA Toxicity Grading Scale;Intensity of Solicited Systemic Adverse Events Per the FDA Toxicity Grading Scale;Intensity of Unsolicited Adverse Events Assessed by the Investigator;Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination;Number of Participants With Grade 3 Adverse Reactions or Any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination;Number of Participants With One or More Adverse Events of Special Interest (AESIs);Number of Participants With One or More Serious Adverse Events (SAEs);Number of Participants With One or More Serious Adverse Events (SAEs) Considered Related to Trial Vaccine;Number of Participants With Solicited Local Adverse Events;Number of Participants With Solicited Systemic Adverse Events;Number of Participants With Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Number of Participants With Unsolicited Adverse Events;Number of Participants With Unsolicited Adverse Events Considered Related to Trial Vaccine

Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events Assessed by the Investigator;Number of Participants with One or More Serious Adverse events (SAEs) Considered Related to Trial Vaccine;Duration of Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Number of Participants with Unsolicited Adverse Events;Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination;Number of Participants with One or More Serious Adverse events (SAEs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine

Intensity of Solicited Systemic Adverse Events per the FDA Toxicity Grading Scale;Intensity of Solicited Local Adverse Events per the FDA Toxicity Grading Scale;Number of Participants with Unsolicited Adverse Events Considered Related to Trial Vaccine;Intensity of Unsolicited Adverse Events Assessed by the Investigator;Number of Participants with One or More Serious Adverse events (SAEs) Considered Related to Trial Vaccine;Duration of Solicited Local Adverse Events;Number of Participants with Solicited Systemic Adverse Events;Duration of Solicited Systemic Adverse Events;Number of Participants with Solicited Local Adverse Events;Number of Participants with One or More Adverse Events of Special Interest (AESIs);Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 24 Hours After the First Vaccination;Number of Participants with Solicited Systemic Adverse Events Considered Related to Trial Vaccine;Number of Participants with Unsolicited Adverse Events;Number of Participants With Grade 3 Adverse Reactions or any Serious Adverse Event (SAE) Considered Related to Trial Vaccine Within at Least 60 Hours After the First Vaccination;Number of Participants with One or More Serious Adverse events (SAEs);Number of Participants with One or More Adverse Events of Special Interest (AESIs) Considered Related to Trial Vaccine